NCT03003364View on ClinicalTrials.gov

Intrathecal Administration of Expanded Wharton's Jelly Mesenchymal Stem Cells in Chronic Traumatic Spinal Cord Injury

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 27, 2016

Primary Completion Date

July 25, 2019

Study Completion Date

February 11, 2020

Conditions

Spinal Cord Injury, Chronic

Interventions

DRUG

XCEL-UMC-BETA

Intrathecal allogeneic cell therapy in a blinded syringe

DRUG

Placebo

Placebo in a blinded syringe

Trial Locations (1)

08916

Hospital de Neurorehabilitació Institut Guttmann, Badalona

All Listed Sponsors

collaborator

Hospital de Neurorehabilitació Institut Guttmann

UNKNOWN

collaborator

Recerca Clínica S.L.

INDUSTRY

collaborator

Syntax for Science, S.L

INDUSTRY

lead

Banc de Sang i Teixits

OTHER

NCT03003364 - Intrathecal Administration of Expanded Wharton's Jelly Mesenchymal Stem Cells in Chronic Traumatic Spinal Cord Injury | Biotech Hunter | Biotech Hunter